Robert G. Perry - Concepedia

Author

Robert G. Perry

Novartis (Switzerland)

Also Known As

Perry, R. Michael, Perry, Robert G, R. Perry, Robert G. Perry, Robert Perry

Publications

935

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research Elite Research Institute Novartis (United States)Novartis (India)

About

Robert G. Perry is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	36
2	Hepatology	2	2	23
3	Engineering	1	1	30
4	Civil Engineering	1	1	30
5	Immunology	1	1	10

Robert G. Perry

Publications

918

Citations

H-Index

Page 1

	Year	Citations
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity Steven B. Heymsfield, Laura A. Coleman, Ram R. Miller, JAMA Network Open	2021	259
Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof‐of‐Concept Study Daniel Rooks, Jens Præstgaard, Sam Hariry, Journal of the American Geriatrics Society	2017	215
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas, Gastroenterology	2021	204
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults Daniel Rooks, Therese Swan, Budhaditya Goswami, JAMA Network Open	2020	144
Groundwater abstraction impacts on spring flow and base flow in the Hillsborough River Basin, Florida, USA Kenneth A. Weber, Robert G. Perry Hydrogeology Journal HydrogeologyEngineeringWater ResourcesSubsurface HydrologyCivil Engineering	2006	30
Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers D J Brazier, Robert G. Perry, Jim Keane, Clinical Drug Investigation	2017	30
Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects Kasra Shakeri‐Nejad, Vassilios Aslanis, Uday Kiran Veldandi, Clinical Therapeutics Heart FailureCardiac RepolarizationCardiovascular DiseaseHealthy SubjectsMedicine	2015	13
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment Erik Mogalian, Diana M. Brainard, Anu Osinusi, Clinical Pharmacokinetics Hepatic DisordersHepatologyLiver PhysiologyHepatic ImpairmentVirology	2018	13
P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT Erik Mogalian, Anita Mathias, D. Brainard, Journal of Hepatology Hepatic DisordersHepatologyViral HepatitisLiver PhysiologyMedicine	2014	10

Page 1